Effects of orally administered Beta-Glucan on leukocyte function in humans, a pilot study

• Conditions: Immune suppression; 10027665

• Registration Number: NL-OMON37015
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

- Written informed consent;
- Age >=18;
- Healthy male;

Exclusion Criteria

- Subjects with a history of allergy or intolerance to Beta-glucan;
- Use of any medication;
- Participation in a drug trial or donation of blood 3 months prior to Beta-glucan administration;
- Use of antibiotics, norit, laxatives (up till 6 months prior to inclusion), cholestyramine, acid burn inhibitors or immune suppressive agents (up till 3 months prior to inclusion), and pre- and probiotics (up till 1 month prior to inclusion).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome measure is the TNF-a secretion by ex vivo LPS-stimulated<br /><br>peripheral blood mononuclear cells (PBMCs).</p><br>